flow trial glp 1 FLOW: The First Dedicated CKD Outcomes With a GLP-1 Receptor Agonist flow trial semaglutide kidney outcomes

[DOI] [PMC free article] [PubMed] [Google Scholar] Vallf D., Kalafateli A.L., Jerlhag E

Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial: The STEP 8 randomized clinical trial

SODIUM-GLUCOSE TRANSPORT PROTEIN 2 (SGLT2) INHIBITORS Introduction There are currently five SGLT2 inhibitors available (Canagliflozin/ Invokana

Neurodiem)

Perfect for breakfast, lunch, and dinner

However, some individuals regain 25-50% of lost weight within 3-5 years due to stomach dilation, stretched pouch capacity, or behavioral factors